Vaccines for Use in Special Populations: Immunocompromised Hosts.
作者信息
Ison Michael G
机构信息
Respiratory Diseases Branch, Division of Microbiology and Infectious, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
出版信息
J Infect Dis. 2025 Mar 17;231(3):552-555. doi: 10.1093/infdis/jiae508.
Abstract
摘要
相似文献
1
Vaccines for Use in Special Populations: Immunocompromised Hosts.特殊人群适用的疫苗：免疫功能低下宿主
J Infect Dis. 2025 Mar 17;231(3):552-555. doi: 10.1093/infdis/jiae508.
2
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.呼吸道合胞病毒相关下呼吸道疾病的估计疫苗效力
JAMA Netw Open. 2024 Dec 2;7(12):e2450832. doi: 10.1001/jamanetworkopen.2024.50832.
3
Respiratory syncytial virus prevention in immunocompromised hosts: gaps and opportunities.免疫功能低下宿主中呼吸道合胞病毒的预防：差距与机遇
Curr Opin Infect Dis. 2025 Aug 1;38(4):300-304. doi: 10.1097/QCO.0000000000001124. Epub 2025 Jun 5.
4
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.新冠病毒疫苗在免疫功能低下人群中的免疫和临床疗效：一项系统评价
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
5
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.免疫球蛋白治疗住院婴儿和幼儿呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD009417. doi: 10.1002/14651858.CD009417.pub3.
6
Respiratory syncytial virus (RSV) infections in adults: Current trends and recommendations for prevention - a global challenge from a local perspective.成人呼吸道合胞病毒（RSV）感染：当前趋势及预防建议——从地方视角看全球挑战
Hum Vaccin Immunother. 2025 Dec;21(1):2514357. doi: 10.1080/21645515.2025.2514357. Epub 2025 Jun 18.
7
In-Hospital Mortality and Severe Respiratory and Renal Outcomes-A Territory-Wide Comparison Between RSV and Influenza.住院死亡率以及严重呼吸和肾脏结局——呼吸道合胞病毒与流感的全地区比较
Influenza Other Respir Viruses. 2025 Jun;19(6):e70130. doi: 10.1111/irv.70130.
8
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.50岁及以上成年人中，mRNA-1345呼吸道合胞病毒疫苗与流感疫苗或新冠疫苗联合接种的安全性和免疫原性：一项观察者盲法、安慰剂对照、随机、3期试验。
Lancet Infect Dis. 2025 Apr;25(4):411-423. doi: 10.1016/S1473-3099(24)00589-9. Epub 2024 Nov 25.
9
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
10
Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2.免疫功能正常和免疫功能低下患者针对不同呼吸道病毒（呼吸道合胞病毒、流感病毒和严重急性呼吸综合征冠状病毒2）的适应性免疫持久性
Vaccines (Basel). 2024 Dec 22;12(12):1444. doi: 10.3390/vaccines12121444.
本文引用的文献
1
How Immunocompromised Hosts Were Left Behind in the Quest to Control the COVID-19 Pandemic.免疫功能低下宿主在控制 COVID-19 大流行的过程中被忽视。
Clin Infect Dis. 2024 Oct 15;79(4):1018-1023. doi: 10.1093/cid/ciae308.
2
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.异基因造血细胞移植或嵌合抗原受体 T 细胞治疗后第一年的 SARS-CoV-2 疫苗接种：一项前瞻性、多中心、观察性研究。
Clin Infect Dis. 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291.
3
Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.呼吸道合胞病毒融合前 F 疫苗接种：抗体持久性和再次接种。
J Infect Dis. 2024 Oct 16;230(4):e905-e916. doi: 10.1093/infdis/jiae185.
4
Prevalence of Immunosuppression Among US Adults.美国成年人中免疫抑制的患病率。
JAMA. 2024 Mar 12;331(10):880-882. doi: 10.1001/jama.2023.28019.
5
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.呼吸道合胞病毒（RSV）预融合F蛋白疫苗（RSVPreF3 OA）在两个RSV流行季节对老年人的疗效和安全性
Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010.
6
Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients.多中心儿科移植受者队列中活病毒疫苗的安全性和免疫原性。
JAMA Netw Open. 2023 Oct 2;6(10):e2337602. doi: 10.1001/jamanetworkopen.2023.37602.
7
American Society of Transplantation and Cellular Therapy Series: #7 - Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.美国移植与细胞治疗学会系列：#7-造血干细胞移植受者呼吸道合胞病毒感染的管理。
Transplant Cell Ther. 2023 Dec;29(12):730-738. doi: 10.1016/j.jtct.2023.09.018. Epub 2023 Sep 30.
8
Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial).高剂量流感疫苗与MF59佐剂流感疫苗及标准流感疫苗在实体器官移植受者中的免疫原性：瑞士/西班牙实体器官移植预防流感试验（STOP-FLU试验）
Clin Infect Dis. 2024 Jan 25;78(1):48-56. doi: 10.1093/cid/ciad477.
9
Vaccine-Preventable Infections Among Solid Organ Transplant Recipients in Switzerland.瑞士实体器官移植受者的疫苗可预防感染。
JAMA Netw Open. 2023 Apr 3;6(4):e2310687. doi: 10.1001/jamanetworkopen.2023.10687.
10
Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023.单价mRNA新冠疫苗在奥密克戎变异株流行期间预防免疫功能正常的成年人新冠病毒相关有创机械通气和死亡方面的有效性——IVY网络，美国19个州，2022年2月1日至2023年1月31日
MMWR Morb Mortal Wkly Rep. 2023 Apr 28;72(17):463-468. doi: 10.15585/mmwr.mm7217a3.
Zotero 插件